Table 6 Rate of safety outcomes for drug users with HCV
Outcomes | Safety | Heterogeneity | Studies | ||
|---|---|---|---|---|---|
Total, n/N | Rate% (95% CI) | I2 (%) | P | ||
Virological relapse | 4/81 | 5.1 (1.9–12.9) | 0.0 | 0.5813 | 2 |
Virological reinfection | 4/71 | 5.7 (2.2–14.2) | 0.0 | 0.7930 | 2 |
Virological failure | 11/250 | 4.8 (2.5–9.0) | 5.3 | 0.3480 | 3 |
AEs | 333/447 | 77.8 (64.5–87.1) | 85.7 | 0.0001 | 4 |
SAEs | 17/368 | 5.3 (1.8–14.5) | 76.2 | 0.0056 | 4 |
Discontinuation due to AEs | 2/453 | 0.5 (0.1–1.8) | 0.0 | 0.8377 | 2 |